Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

John R. Wingard, Paul Kubilis, Lily Lee, Gary Yee, Mary White, Louise Walshe, Raleigh Bowden, Elias Anaissie, John Hiemenz, John Lister

Research output: Contribution to journalArticle

309 Citations (Scopus)

Abstract

The records of 239 immunosuppressed patients receiving amphotericin B for suspected or proven aspergillosis were reviewed to determine rates of nephrotoxicity, dialysis, and fatality. The mean and median durations of treatment were 20.4 and 15.0 days, respectively. The creatinine level doubled in 53% of patients and exceeded 2.5 mg/dL in 29%; 14.5% underwent dialysis; and 60% died. A multivariate Cox proportional hazards analysis showed that patients whose creatinine level exceeded 2.5 mg/dL (hazard ratio [HR], 42.02; P < .001), allogeneic bone marrow transplantation (BMT) patients (HR, 6.34; P < .001), and autologous BMT patients (HR, 5.06; P = .024) were at greatest risk for requiring hemodialysis. Use of hemodialysis (HR, 3.089; P < .001), duration of amphotericin B use (HR, 1.03 per day; P = .015), and use of nephrotoxic agents (HR, 1.96; P = .017) were associated with greater risk of death, whereas patients undergoing solid organ transplantation were at lowest risk (HR, 0.46; P = .002). These data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups.

Original languageEnglish (US)
Pages (from-to)1402-1407
Number of pages6
JournalClinical Infectious Diseases
Volume29
Issue number6
DOIs
StatePublished - Dec 1 1999

Fingerprint

Aspergillosis
Amphotericin B
Renal Dialysis
Creatinine
Bone Marrow Transplantation
Dialysis
Autologous Transplantation
Homologous Transplantation
Organ Transplantation
Odds Ratio
Mortality
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. / Wingard, John R.; Kubilis, Paul; Lee, Lily; Yee, Gary; White, Mary; Walshe, Louise; Bowden, Raleigh; Anaissie, Elias; Hiemenz, John; Lister, John.

In: Clinical Infectious Diseases, Vol. 29, No. 6, 01.12.1999, p. 1402-1407.

Research output: Contribution to journalArticle

Wingard, JR, Kubilis, P, Lee, L, Yee, G, White, M, Walshe, L, Bowden, R, Anaissie, E, Hiemenz, J & Lister, J 1999, 'Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis', Clinical Infectious Diseases, vol. 29, no. 6, pp. 1402-1407. https://doi.org/10.1086/313498
Wingard, John R. ; Kubilis, Paul ; Lee, Lily ; Yee, Gary ; White, Mary ; Walshe, Louise ; Bowden, Raleigh ; Anaissie, Elias ; Hiemenz, John ; Lister, John. / Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. In: Clinical Infectious Diseases. 1999 ; Vol. 29, No. 6. pp. 1402-1407.
@article{911f224f07af477296fc6986cf67b43a,
title = "Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis",
abstract = "The records of 239 immunosuppressed patients receiving amphotericin B for suspected or proven aspergillosis were reviewed to determine rates of nephrotoxicity, dialysis, and fatality. The mean and median durations of treatment were 20.4 and 15.0 days, respectively. The creatinine level doubled in 53{\%} of patients and exceeded 2.5 mg/dL in 29{\%}; 14.5{\%} underwent dialysis; and 60{\%} died. A multivariate Cox proportional hazards analysis showed that patients whose creatinine level exceeded 2.5 mg/dL (hazard ratio [HR], 42.02; P < .001), allogeneic bone marrow transplantation (BMT) patients (HR, 6.34; P < .001), and autologous BMT patients (HR, 5.06; P = .024) were at greatest risk for requiring hemodialysis. Use of hemodialysis (HR, 3.089; P < .001), duration of amphotericin B use (HR, 1.03 per day; P = .015), and use of nephrotoxic agents (HR, 1.96; P = .017) were associated with greater risk of death, whereas patients undergoing solid organ transplantation were at lowest risk (HR, 0.46; P = .002). These data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups.",
author = "Wingard, {John R.} and Paul Kubilis and Lily Lee and Gary Yee and Mary White and Louise Walshe and Raleigh Bowden and Elias Anaissie and John Hiemenz and John Lister",
year = "1999",
month = "12",
day = "1",
doi = "10.1086/313498",
language = "English (US)",
volume = "29",
pages = "1402--1407",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

AU - Wingard, John R.

AU - Kubilis, Paul

AU - Lee, Lily

AU - Yee, Gary

AU - White, Mary

AU - Walshe, Louise

AU - Bowden, Raleigh

AU - Anaissie, Elias

AU - Hiemenz, John

AU - Lister, John

PY - 1999/12/1

Y1 - 1999/12/1

N2 - The records of 239 immunosuppressed patients receiving amphotericin B for suspected or proven aspergillosis were reviewed to determine rates of nephrotoxicity, dialysis, and fatality. The mean and median durations of treatment were 20.4 and 15.0 days, respectively. The creatinine level doubled in 53% of patients and exceeded 2.5 mg/dL in 29%; 14.5% underwent dialysis; and 60% died. A multivariate Cox proportional hazards analysis showed that patients whose creatinine level exceeded 2.5 mg/dL (hazard ratio [HR], 42.02; P < .001), allogeneic bone marrow transplantation (BMT) patients (HR, 6.34; P < .001), and autologous BMT patients (HR, 5.06; P = .024) were at greatest risk for requiring hemodialysis. Use of hemodialysis (HR, 3.089; P < .001), duration of amphotericin B use (HR, 1.03 per day; P = .015), and use of nephrotoxic agents (HR, 1.96; P = .017) were associated with greater risk of death, whereas patients undergoing solid organ transplantation were at lowest risk (HR, 0.46; P = .002). These data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups.

AB - The records of 239 immunosuppressed patients receiving amphotericin B for suspected or proven aspergillosis were reviewed to determine rates of nephrotoxicity, dialysis, and fatality. The mean and median durations of treatment were 20.4 and 15.0 days, respectively. The creatinine level doubled in 53% of patients and exceeded 2.5 mg/dL in 29%; 14.5% underwent dialysis; and 60% died. A multivariate Cox proportional hazards analysis showed that patients whose creatinine level exceeded 2.5 mg/dL (hazard ratio [HR], 42.02; P < .001), allogeneic bone marrow transplantation (BMT) patients (HR, 6.34; P < .001), and autologous BMT patients (HR, 5.06; P = .024) were at greatest risk for requiring hemodialysis. Use of hemodialysis (HR, 3.089; P < .001), duration of amphotericin B use (HR, 1.03 per day; P = .015), and use of nephrotoxic agents (HR, 1.96; P = .017) were associated with greater risk of death, whereas patients undergoing solid organ transplantation were at lowest risk (HR, 0.46; P = .002). These data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups.

UR - http://www.scopus.com/inward/record.url?scp=0033376314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033376314&partnerID=8YFLogxK

U2 - 10.1086/313498

DO - 10.1086/313498

M3 - Article

C2 - 10585786

AN - SCOPUS:0033376314

VL - 29

SP - 1402

EP - 1407

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -